Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Contract Award

27 Nov 2006 13:49

Angle PLC27 November 2006 For Immediate Release 27 November 2006 ANGLE plc ('ANGLE' or 'the Company') Contract Award ANGLE is pleased to announce that it has won a contract with the Carbon Trust toprovide commercial expertise to businesses that demonstrate cost-effective,carbon-reducing solutions. This contract is a continuation of the successful activity undertaken by ANGLEfor the Carbon Trust over the last two years. During this time ANGLE has workedwith 14 early-stage businesses under the programme delivering business planningadvice and development support. The Carbon Trust pays ANGLE up to £65,000 percompany to provide them with business advice. CT-ANGLE Incubator companies have enjoyed considerable success to date raisingover £25 million investment whilst in the incubator, including two companies,CMR Fuel Cells and Oxford Catalysts that have listed on AIM. It is the intention of both ANGLE and the Carbon Trust to build on the successof the Incubator programme, delivering greater support to a greater number ofcompanies. The new contract is for two years with the facility to extend it fora further year. The Carbon Trust plans considerable marketing activities toattract a greater number of companies, whilst ANGLE intends to uses its growingpartnership network, such as the recently announced intellectual propertyframework with the University of Reading, to source further suitable companies. Andrew Newland, Chief Executive of ANGLE said: "The award of this contract recognises the key role that ANGLE can play indeveloping the low carbon technology companies of the future. This is a growthmarket and we believe our participation in Carbon Trust's programme will yieldsubstantial business opportunities over and above the contract itself." For further information ANGLE plc +44 (0)1483 295830Andrew Newland, Chief Executive Buchanan Communications +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from offices inthe UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com About The Carbon Trust The Carbon Trust works with UK business and the public sector to cut carbonemissions and develop commercial low carbon technologies. An independent companyset up by Government to help the UK meet its climate change obligations, theCarbon Trust creates practical business-focused solutions to carbon emissionreduction on energy efficiency, carbon management, and investment. The Carbon Trust's annual funding is in excess of £105m in grants from theDepartment for Environment, Food and Rural Affairs (Defra), the Department ofTrade and Industry(DTI), the Scottish Executive, the Welsh Assembly Governmentand Invest NI. For more information on the Carbon Trust visit www.carbontrust.co.uk or call theCarbon Trust on 0800 085 2005. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.